SCM
XBI icon

Sollinda Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Sollinda Capital Management’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,677
Closed -$239K – 104
2023
Q4 		$239K Buy
+2,677
New +$199K 0.07% 76

Other funds holding XBI

Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Sollinda Capital Management's XBI Position: Q1 2024 in Review

Sollinda Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2024, closing a stake of 2,677 shares — an estimated $239K sold.

Sollinda Capital Management first reported a position in XBI in Q4 2023 and held it in 1 quarter. The position peaked at $239K in Q4 2023. 782 funds tracked by Wall St. Rank hold XBI as of Q1 2024.

  • Sollinda Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2024 after selling out during the quarter.
  • Sollinda Capital Management sold 2,677 State Street SPDR S&P Biotech ETF shares in Q1 2024, an estimated $239K.
  • Sollinda Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2023 and held it in 1 quarter.
  • Sollinda Capital Management's State Street SPDR S&P Biotech ETF position peaked at $239K in Q4 2023.
  • 782 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2024.

Based on Sollinda Capital Management's 13F filing for Q1 2024, filed 22 Apr 2024.